HSP60与支气管哮喘相关性的探讨  

HSP60 and bronchial asthma

作　　者：龚素波[1] 李坑[1] 徐礼[1] 马礼兵[1] 张莉[1] 欧阳若芸[1] 向旭东[1] 

机构地区：[1]中南大学湘雅二医院呼吸内科,长沙410011

出　　处：《国际呼吸杂志》2013年第1期32-36,共5页International Journal of Respiration

摘　　要：支气管哮喘（简称哮喘）是以气道高反应为特征的慢性气道炎症。目前哮喘的治疗局限在控制临床症状上，因此应用更广泛的治疗手段亟待大家去探索。CD4＋T淋巴细胞在哮喘的气道炎症、黏液产生、气道高反应性中起了极其重要的作用。近年来有研究发现热休克蛋白60（heatshockprotein60，HSP60）能够介导CD4＋T淋巴细胞的分化，提示HSP60可能成为治疗哮喘的新靶点，尤其是重症哮喘和难治性哮喘。本文旨在就目前的关于HSP60和哮喘关系的研究作一综述。Bronchial asthma （asthma） is a chronic and complex airway inflammatory disease characterized by airway hyper-responsiveness. Current asthma therapies are limited to specific disease manifestations, highlighting the importance of developing treatments with broader treatment applications. CD4＋ T lymphocytes, which produce a characteristic repertoire of cytokines, play a critical role in the development of airway inflammation, mucus production and airway hyper-responsiveness in asthma. Recently, it has been demonstrated that heat shock protein 60 （HSP60） could mediate CD4＋ T lymphocyte differentiation, suggesting that HSP60 can be targeted in the development of novel anti- asthma medications, especially for the treatment of severe disease or refractory patients. This review summarizes the current knowledge regarding the relationship between HSP60 and asthma.

关 键 词：热休克蛋白60 CD4+T淋巴细胞 支气管哮喘 

分 类 号：R562.25[医药卫生—呼吸系统]